Dual GLP-1/GIP Agonists for Weight Reduction and Cardiovascular Outcomes in Type 2 Diabetes
2026 | IAA Journal of Scientific Research | Pp. 65-70
Type 2 diabetes mellitus (T2DM) was characterized by hyperglycemia and frequently accompanied by obesity and elevated cardiovascular risk. Incretin hormone-based therapies, especially glucagon-like peptide-1 receptor agonists (GLP-1 RAs), had demonstrated eff...